0001209191-22-041337.txt : 20220706 0001209191-22-041337.hdr.sgml : 20220706 20220706182121 ACCESSION NUMBER: 0001209191-22-041337 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220705 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lubner David Charles CENTRAL INDEX KEY: 0001572000 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 221070079 MAIL ADDRESS: STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC. STREET 2: 480 ARSENAL STREET, SUITE 110 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-05 0 0001818794 Dyne Therapeutics, Inc. DYN 0001572000 Lubner David Charles C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD WALTHAM MA 02451 1 0 0 0 Stock Option (right to buy) 5.54 2022-07-05 4 A 0 7222 0.00 A 2030-07-30 Common Stock 7222 7222 D The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. /s/ Richard Scalzo, Attorney-in-Fact 2022-07-06